AutoGenomics and McKesson Medical-Surgical Inc. enter into Distribution Agreement

Vista, CA -- AutoGenomics, Inc., a leader in providing automated
molecular testing solutions, announced today that it has entered into an
agreement whereby McKesson Medical-Surgical Inc. and AutoGenomics will jointly
distribute the AutoGenomics’ INFINITI® molecular diagnostic systems and related
reagent and consumables products throughout the United States

AutoGenomics’ molecular diagnostics proprietary technology
platform is in use globally in clinical reference laboratories, contract
research organizations (CRO’s), specialty clinics and hospital laboratories.
The platform consists of a family of INFINITI® analyzers including the
INFINITI® PLUS, a prepared sample to answer system, and the INFINITI® High
Throughput System, which has the capability of producing over 6,000 patient
results per day. The platform also includes five FDA cleared tests and a menu
of over 60 genetic tests for potential application in the areas of personalized
medicine (pain management, cardiovascular health assessment and mental health
therapy), women’s health, oncology, infectious diseases and genetic disorders.

McKesson Medical-Surgical Inc., an affiliate of McKesson
Corporation, offers healthcare products and distribution services, solutions
and clinical support to a wide range of healthcare providers including
physicians’ offices, hospitals and clinical reference laboratories

“We believe that our partnership with McKesson
Medical-Surgical Inc., with its extensive distribution network, will broaden
the market for our INFINITI® platform and related genetic tests as healthcare
in the United States enters the era of Precision Medicine,” said Fareed
Kureshy, President and Chief Executive Officer of AutoGenomics.

About AutoGenomics

AutoGenomics Inc., a privately held company based in Vista,
CA, developed the first automated, microarray based multiplexing diagnostic
platform that can be used to assess disease signatures with novel genomic and
proteomic markers in the area of pharmacogenomics, genetic disorders,
infectious disease and oncology. With the discovery of genes and their link to
various disease states, the platform has the
versatility to revolutionize the way patients are diagnosed, monitored and
managed, leading to the era of precision medicine. www.autogenomics.com.

About McKesson Medical-Surgical Inc.

McKesson Medical-Surgical Inc., with offices in Richmond,
Va., is an affiliate of McKesson Corporation. McKesson Corporation, currently
ranked 11th on the FORTUNE 500, is a healthcare services and information
technology company dedicated to making the business of healthcare run better.
McKesson Medical-Surgical works with payers, hospitals, physician offices,
pharmacies, pharmaceutical companies and others across the spectrum of care to
build healthier organizations that deliver better care to patients in every
setting. McKesson Medical-Surgical helps its customers improve their financial,
operational, and clinical performance with solutions that include
pharmaceutical and medical-surgical supply management, healthcare information
technology, and business and clinical services. For more information, visit
http://www.mckesson.com.

Fareed Kureshy
President and Chief Executive Officer
(760) 477-2248 ext. 306
fkureshy@autogenomics.com

AutoGenomics and McKesson Medical-Surgical Inc. enter into Distribution Agreement